Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2017 at "ESMO Open"
DOI: 10.1136/esmoopen-2016-000108
Abstract: Objective Nivolumab is a fully human IgG4 programmed cell death 1 immune checkpoint inhibitor monoclonal antibody approved for the treatment of non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the… read more here.
Keywords: non squamous; japanese patients; recurrent non; patients advanced ... See more keywords
Efficacy and safety of nivolumab for advanced/recurrent non-small-cell lung cancer: an up-to-date meta-analysis of large-scale phase III randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0081
Abstract: Aim: To evaluate the efficacy and safety of nivolumab for advanced/recurrent non-small-cell lung cancer (NSCLC). Methods: Electronic databases were searched, and a systematic evaluation was performed. Results: Seven phase III randomized controlled trials and 4705… read more here.
Keywords: safety nivolumab; advanced recurrent; nivolumab advanced; efficacy safety ... See more keywords
Signature of Circulating Biomarkers in Recurrent Non-Infectious Anterior Uveitis. Immunomodulatory Effects of DHA-Triglyceride. A Pilot Study
Sign Up to like & getrecommendations! Published in 2021 at "Diagnostics"
DOI: 10.3390/diagnostics11040724
Abstract: The purpose of this study was to identify circulating biomarkers of recurrent non-infectious anterior uveitis (NIAU), and to address the anti-inflammatory effects of triglyceride containing docosahexaenoic acid (DHA-TG). A prospective multicenter study was conducted in… read more here.
Keywords: circulating biomarkers; biomarkers recurrent; study; recurrent non ... See more keywords